A5035654935- Glioma Diagnosis and Treatment
- Brain Metastases and Treatment
- Dementia and Cognitive Impairment Research
- Pituitary Gland Disorders and Treatments
- Cancer, Hypoxia, and Metabolism
- Cancer Treatment and Pharmacology
- Ocular Oncology and Treatments
- Cancer Genomics and Diagnostics
- Meningioma and schwannoma management
- Cancer Immunotherapy and Biomarkers
- Cancer Research and Treatments
- Colorectal Cancer Treatments and Studies
- Radiomics and Machine Learning in Medical Imaging
- Esophageal Cancer Research and Treatment
- Lung Cancer Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Alzheimer's disease research and treatments
- Functional Brain Connectivity Studies
- Vascular Malformations Diagnosis and Treatment
- Neurofibromatosis and Schwannoma Cases
- Pancreatic and Hepatic Oncology Research
- Medical Imaging Techniques and Applications
- Neuroblastoma Research and Treatments
- Hearing Loss and Rehabilitation
- Health Systems, Economic Evaluations, Quality of Life
Alliance Data (United States)
2017-2023
Mayo Clinic
2017-2023
Mayo Clinic in Arizona
2019-2023
Mayo Clinic in Florida
2022-2023
To evaluate the use of early assessment chemotherapy responsiveness by positron emission tomography (PET) imaging to tailor therapy in patients with esophageal and esophagogastric junction adenocarcinoma.
Craniopharyngiomas, primary brain tumors of the pituitary-hypothalamic axis, can cause clinically significant sequelae. Treatment with use surgery, radiation, or both is often associated substantial morbidity related to vision loss, neuroendocrine dysfunction, and memory loss. Genotyping has shown that more than 90% papillary craniopharyngiomas carry
Patients with progressive or recurrent meningiomas have limited systemic therapy options. Focal adhesion kinase (FAK) inhibition has a synthetic lethal relationship
Abstract Background The benefit of immune checkpoint blockade in mCRC is currently limited to mismatch repair (MMR) deficient tumours. Increasing evidence suggests that the vascular endothelial growth factor (VEGF) pathway plays a role cancer evasion. Co-targeting PD-1/PD-L1 and VEGF axes may result clinical activity mCRC. Methods 133 patients (pts) were randomized 2:1 receive C/B/P (Arm A) or C/B/A B), stratifying by ECOG RAS. Pts had progressed on 5-FU, oxaliplatin, irinotecan,...
Src signaling is markedly upregulated in patients with invasive glioblastoma (GBM) after the administration of bevacizumab. The family kinase inhibitor dasatinib has been found to effectively block bevacizumab-induced glioma invasion preclinical models, which led hypothesis that combining bevacizumab could increase efficacy recurrent GBM.After completion phase 1 component, 2 trial (ClinicalTrials.gov identifier NCT00892177) randomized GBM 2:1 receive 100 mg oral twice daily (arm A) or...
BACKGROUND Mitogen‐activated protein kinase (MAPK) activation and mammalian target of rapamycin (mTOR)‐dependent signaling are hallmarks glioblastoma. In the current study, authors conducted a phase 1/2 study sorafenib (an inhibitor Raf vascular endothelial growth factor receptor 2 [VEGFR‐2]) mTOR temsirolimus in patients with recurrent METHODS Patients glioblastoma who developed disease progression after surgery or radiotherapy plus temozolomide ≤2 prior chemotherapy regimens were eligible....
591 Background: Both Cb and Bev demonstrate activity when combined with standard chemotherapy in TNBC. CALGB 40603 is a 2x2 randomized trial that previously demonstrated adding to NACT significantly increased pathologic complete responses the breast/axilla (pCR), while did not (Sikov, JCO 2015). Here we report 5-year LTOs assess factors influenced them. Methods: 443 patients clinical stage II-III untreated TNBC received 12 weeks of paclitaxel (wP) +/- then dose-dense AC, before surgery. The...
4012 Background: We evaluated use of early PET response after induction chemotherapy (CT) to direct changing alternative CT during preoperative chemoradiation (CRT) among patients (pts) with resectable esophageal and gastroesophageal junction (GEJ) adenocarcinomas who are nonresponders. previously reported the primary endpoint improving pathologic complete (pCR) in nonresponders; pre-specified efficacy criteria were met for improvement pCR rates CRT. now report survival outcomes by status....
2502 Background: Patients with progressive or recurrent meningiomas have limited treatment options. Clinical trials of systemic therapies for failed to demonstrate benefit. FAK inhibition has a synthetic lethal relationship NF2 loss. Given the predominance mutations in meningiomas, we evaluated efficacy GSK2256098, inhibitor, as part first genomically-driven phase II study grade I-III meningiomas. Methods: Eligible patients (pts) whose tumors screened positively were treated GSK2256098 750mg...
2000 Background: Craniopharyngiomas, a rare brain tumor along the pituitary-hypothalamic axis, can cause significant clinical sequelae. Surgery and radiation, only effective treatments, morbidity. Genetic analysis of craniopharyngiomas revealed that 95% papillary (PCP) have BRAF V600E mutations (Brastianos et al. Nature Genetics 2014). We evaluated efficacy BRAF/MEK inhibition in patients (pts) with previously untreated PCP. Methods: Eligible pts without prior radiation whose PCP screened...
Abstract Background A recent phase III trial (NCT01372774) comparing use of stereotactic radiosurgery [SRS] versus whole-brain radiation therapy [WBRT] after surgical resection a single brain metastasis revealed that declines in cognitive function were more common with WBRT than SRS. secondary endpoint trial, and the primary objective this analysis, was to identify baseline biomarkers associated impairment either form radiotherapy for metastasis. Here we report our findings on APOE genotype...
Abstract Introduction We aimed to define a Mayo Preclinical Alzheimer's disease Cognitive Composite (Mayo‐PACC) that prioritizes parsimony and use of public domain measures facilitate clinical translation. Methods Cognitively unimpaired participants aged 65 85 at baseline with amyloid PET imaging were included, yielding 428 negative (A‐) 186 positive (A+) individuals 7 years mean follow‐up. Sensitivity amyloid‐related cognitive decline was examined using slope estimates derived from linear...
Patients with glioblastoma (GBM) have a poor prognosis and limited effective treatment options. Bevacizumab has been approved for of recurrent GBM, but there is questionable survival benefit. Based on preclinical early clinical data indicating that CD105 upregulation may represent mechanism resistance to bevacizumab, we hypothesized combining bevacizumab the anti-CD105 antibody TRC105 improve efficacy in GBM.Phase I dose-escalation/comparative randomized phase II trial patients GBM. During...
2023 Background: TRC105 is a humanized antibody targeting CD105 (endoglin), member of the TGFβ receptor superfamily. expressed in glioma stem cells and circulating endothelial (CECs) GBM patients (pts), increasing following VEGF inhibition. N1174 was conducted recurrent bevacizumab (bev) naïve pts to investigate hypothesis that blockade+bev can delay development bev resistance. Methods: After ph I cohort (15 pts) established II dose as 10 mg/kg IV over 4 hours every 7 days combination with...
TPS2573 Background: Brain metastases, most commonly derived from melanoma, lung and breast cancers, are the common brain tumor, with approximately 200,000 cases diagnosed annually in United States. Median survival is on order of months. For patients clinically symptomatic half succumb due to intracranial progression. In preclinical work, we demonstrated that metastases primary tumors often genetically distinct frequent alterations CDK PI3K pathway (Brastianos, Carter et al. Cancer Discovery...
TPS2085 Background: Glioblastoma (GBM) is the most common and aggressive form of brain tumor in adults. Despite maximal surgical resection, irradiation, chemotherapy, median overall survival (OS) remains at only 30 weeks for recurrent GBM (rGBM) patients, emphasizing need novel treatments. tumors are immunologically ‘cold,’ that they have an immune-suppressive microenvironment with a low number tumor-infiltrating lymphocytes (TIL). Interleukin 7 (IL-7) plays key role T cell development...
BACKGROUND AND OBJECTIVES: Despite standard of care with maximal safe resection and chemoradiation, glioblastoma (GBM) is the most common aggressive type primary brain cancer. Surgical provides a window opportunity to locally treat gliomas while patient recovering before initiating concomitant chemoradiation. The objective was assess safety establish maximum tolerated dose adipose-derived mesenchymal stem cells (AMSCs) for treatment recurrent GBM. Secondary objectives were toxicity profile...
TPS3154 Background: Immune-related Adverse Events (irAEs) are rare but serious sequelae of treatment with immuno-oncology (IO) therapeutics. These therapeutics, including monoclonal antibodies targeting programmed cell death protein 1 (PD-1), death-ligand (PD-L1) and cytotoxic T-lymphocyte-associated 4 (CTLA-4), have had transformative effects on outcomes for patients (pts) advanced cancers. Although most pts tolerate the therapies well, a few experience irAEs ranging in severity up to...
Abstract Background Remote assessment tools offer significant promise for aiding early detection of cognitive impairment. Mayo Test Drive (MTD): Development through Rapid Iteration, Validation and Expansion, is a web‐based platform remote self‐administered that includes computer adaptive word list memory test (Stricker Learning Span; SLS) measure processing speed (Symbols Test). We examined the diagnostic accuracy SLS MTD composite (SLS max span, trials 1–5 total correct, delay [Symbols...
Abstract Background Preclinical Alzheimer’s cognitive composites (PACC) are designed to detect subtle changes in clinical trials. PACCs often include measures of memory, attention, and semantic fluency, with variations based on available measures. We created a Mayo Clinic PACC (Mayo‐PACC) address limitations existing by prioritizing parsimony, non‐proprietary measures, applicability, psychometric properties. developed Mayo‐PACC examined sensitivity detecting longitudinal change amyloid...
Abstract BACKGROUND Craniopharyngiomas, primary brain tumors of the pituitary-hypothalamic axis, can cause significant clinical sequelae. Treatment using surgery, radiation, or both often entails morbidity. In prior work, we demonstrated that ninety-five percent papillary craniopharyngiomas (PCP) harbor BRAF V600E mutations (Brastianos et al. Nature Genetics 2014). this multicenter National Cancer Institute cooperative group trial (Alliance A071601), evaluated safety and efficacy BRAF/MEK...